Effect of Quetiapine on Brain Activity Patterns in Patients With Heightened Risk of Bipolar Disorder

NCT ID: NCT02451306

Last Updated: 2015-05-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2018-05-31

Brief Summary

Bipolar disorder (BPD) is often misdiagnosed as unipolar depression. This leads to inadequate treatment and can have negative impact on the course of the disease. There is now preliminary evidence that patients with unipolar and bipolar depression as well as healthy individuals with a heightened risk of BPD can be distinguished from each other based on their brain activity patterns and functional connectivity during resting state.

However, the impact of pharmacological treatment on these functional brain measures have not yet been clarified. For common antidepressants it has been shown that they seem to normalise aberrant brain activity patterns and functional connectivity. The problem is that some antidepressants can induce mania or accelerate pathological cycling in depressive patients with unrecognised BPD. Therefore, pharmacological drugs with mood-stabilising properties such as quetiapine are more and more prescribed. Although the effectiveness and tolerability have been proven, the neuronal effects of these adjunctive treatments are not clear. The aim of the study is thus to investigate the impact of quetiapine on measures of brain activity in depressive patients with a heightened risk of BPD. Moreover, the investigators want to examine whether the investigators can distinguish depressive patients with a heightened risk of BPD from depressive patients without a heightened risk of BPD using neuroimaging techniques, and whether these measures can predict the course of the disease.

Conditions

Depression; Bipolar Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Quetiapine

18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.

Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole.

Group Type: EXPERIMENTAL

Quetiapine

Intervention Type: DRUG

See information in arm description.

Placebo

18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.

The placebo does not contain any psychoactive substance.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

See information in arm description.

Control-group

18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Quetiapine

See information in arm description.

Intervention Type: DRUG

Placebo

See information in arm description.

Intervention Type: DRUG

Other Intervention Names

Seroquel Prolong

Eligibility Criteria

Inclusion Criteria

• diagnosis of depressive episode (F32.X, F33.X) with duration less than < 6 months
• max. three previous episodes of illness
• no manic or hypomanic episodes in the past
• current treatment with one antidepressant
• MRI-compatibility
• unequivocal understanding of study information and autonomous consent
• for women: negative pregnancy test
• for risk-group:

• 14 or more points on hypomania checklist (HCL-32)
• additionally at least one of the following four risk factors:

1. positive family history (i.e. first or second order relatives with BPD, schizoaffective or schizophrenic psychosis, mania or suicide attempt)

2. initial manifestation before 30 years of age

3. initial manifestation after childbirth

4. suicide attempt in the past

Exclusion Criteria

• additional diagnoses of psychiatric disorders (Organic, including symptomatic, mental disorders [F0X.X]; mental and behavioural disorders due to psychoactive substance use [F1X.X]; schizophrenia, schizotypal and delusional disorders [F2X.X]; mental retardation [F7X.X])
• chronic or acute physical disease
• individuals who are in a dependence- or work-relation with the sponsor
• limited or annulled legal capacity
• court or administrative order for hospitalisation
• for women: pregnancy, nursing period or unsafe contraceptive methods
• for the risk group:

• clinical relevant changes in clinical chemistry, hematology, EEG or EKG
• known contraindication for quetiapine (e.g. hypersensitivity to [active] ingredient[s], HIV-protease inhibitors, antimycotics, antibiotics)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RWTH Aachen University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Frank Schneider, Univ.-Prof.

Role: STUDY_DIRECTOR

University Hospital, Aachen

Locations

Clinic for psychiatry, psychotherapy and psychosomatic, RWTH Aachen University Hospital

Aachen, North Rhine-Westphalia, Germany

Countries

Germany

Central Contacts

Lina Winkler, M.Sc.

Role: CONTACT

liwinkler@ukaachen.de

Other Identifiers

EK018/15

Identifier Type: -

Identifier Source: org_study_id